Inotrem bolsters leadership team with the appointment of Sven Zimmermann as new CEO

Paris. March 24, 2021. Inotrem, an advanced clinical stage biotech company specialized in immunotherapies for acute and chronic inflammatory syndromes, announced today the appointment of Sven Zimmermann as Chief Executive Officer, effective April 19th, 2021. Sven brings an extensive leadership experience in biotech companies’ financial and corporate strategy.

Read full article (PDF) 

luctus tristique ipsum consectetur commodo ultricies nunc